EUVIMEDEUVIMED entdecken
Fallbericht

Autoimmune encephalitis and hepatitis after SARS-CoV-2: a case of multiple autoantibodies

Alexandros Giannakis iD, Ilias Tsiakas, Ioanna Saralioti, Spiridon Konitsiotis

Laboratory Medicine · 2026

DOI: 10.1093/labmed/lmaf058 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Laboratory Medicine, 2026. Verfasst von Alexandros Giannakis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. Hauptthemen laut MEDLINE: COVID-19, Autoantibodies, Hashimoto Disease, Hepatitis, Autoimmune. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Autoimmune encephalitis can occur in isolation or as a postinfectious complication, such as following infection with SARS-CoV-2.

Methods

A patient presented with neuropsychiatric symptoms 3 weeks after SARS‑CoV‑2 infection, including dysphagia, psychosis, and partial-onset seizures. The patient tested positive for anti–N-methyl-d-aspartate receptor antibodies in cerebrospinal fluid as well as anti–γ-aminobutyric acid type A receptor and anti–glutamic acid decarboxylase antibodies in the serum. Findings from brain magnetic resonance imaging and electroencephalography were unremarkable. Cerebrospinal fluid analysis revealed 3 white blood cells/μL, slightly elevated total protein levels (3.16 mmol/L [reference range, 0.83-2.50 mmol/L]), normal blood glucose levels (3.44 mmol/L [reference range, 2.22-3.88 mmol/L]), and negative results on Gram stain and cytologic examination. Nevertheless, a diagnosis of autoimmune encephalitis was established. After 3 months, elevated liver enzyme levels and positive anti–liver-kidney microsomal type 1, anti–smooth muscle, and anti–α-actinin antibodies led to liver biopsy and diagnosis of autoimmune hepatitis.

Results

The patient was treated with repeated pulses of intravenous methylprednisolone, followed by rituximab administered every 6 months for 2 years, resulting in complete recovery.

Discussion

This unprecedented case raises a high index of suspicion for autoimmune states in patients presenting with compatible clinical features, even when typical laboratory findings are unremarkable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AutoantibodiesHashimoto DiseaseHepatitis, AutoimmuneEncephalitisHumansSARS-CoV-2MaleMethylprednisoloneMiddle AgedRituximab

Stichwörter der Autor:innen

anti–N-methyl-d-aspartate receptor antibodiesautoimmune encephalitisautoimmune hepatitisgamma-aminobutyric acid A receptor antibodiesglutamate decarboxylase antibodiessevere acute respiratory syndrome coronavirus 2

Substanzen

AutoantibodiesMethylprednisoloneRituximab

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
  • Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

ORCID-Profile: Alexandros Giannakis

Zitieren

APA

Giannakis, A., Tsiakas, I., Saralioti, I., & Konitsiotis, S. (2026). Autoimmune encephalitis and hepatitis after SARS-CoV-2: a case of multiple autoantibodies. Laboratory Medicine. https://doi.org/10.1093/labmed/lmaf058

Vancouver

Giannakis A, Tsiakas I, Saralioti I, Konitsiotis S. Autoimmune encephalitis and hepatitis after SARS-CoV-2: a case of multiple autoantibodies. Laboratory Medicine. 2026. doi:10.1093/labmed/lmaf058

BibTeX
@article{Giannakis2026,
  author = {Giannakis, Alexandros and Tsiakas, Ilias and Saralioti, Ioanna and Konitsiotis, Spiridon},
  title = {Autoimmune encephalitis and hepatitis after SARS-CoV-2: a case of multiple autoantibodies},
  journal = {Laboratory Medicine},
  year = {2026},
  doi = {10.1093/labmed/lmaf058}
}
Kostenlos starten →